On April 26th, the Covid-19 inactivated vaccine of China Bio-Omicron mutant of Sinopharm Group won the clinical approval of the State Food and Drug Administration. In China, a randomized, double-blind, cohort study will be conducted in order to evaluate the safety and immunogenicity of Omicron variant Covid-19 inactivated vaccine among people aged 18 and above who have completed 2 or 3 doses of COVID-19 vaccination。
Dose Chinese people will welcome a new turn of vaccination?
简体中文 
Deutsche 
русский 
Español 
português 
Italian 
한국어 
عربى 
Türk 
हिंदी 
ไทย